Pipeline

Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials and has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. The European Commission has granted orphan designation to batiraxcept for the treatment of platinum-resistant ovarian cancer.

Analysis of all safety data to date showed that batiraxcept has been generally well tolerated with no dose-limiting toxicities or unexpected safety signals. A P1B platinum-resistant ovarian cancer trial (N = 53) demonstrated more than a doubling of progression-free survival in a patient subgroup that represents the P3 population.